Clinical Trials Directory

Trials / Completed

CompletedNCT04696406

Multicenter, Multinational, Clinical Trial of the Performance of RESPINOR DXT to Identify Patients at Increased Risk of Weaning Failure

Status
Completed
Phase
Study type
Observational
Enrollment
193 (actual)
Sponsor
Respinor AS · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study will be a multicenter, multinational, prospective single arm blinded study to validate DXT's performance to identify patients at increased risk of weaning failure during the spontaneous breathing trial (SBT). Continuous diaphragmatic excursion measurements by DXT will be conducted during the patients' first SBT. The recording shall be initiated 15 minutes prior to the first SBT and will end 15 minutes post SBT. All patients on mechanical ventilation in the ICU meeting the eligibility criteria shall undergo a daily screen for weaning readiness. If any of the components of the daily screen is not met, the patient will not undergo a SBT that day and continued to be screened daily. Patients passing daily screening criteria shall automatically receive an SBT. The SBT shall last for 30-120 minutes and be performed on continuous positive airway pressure up to 5 cm H2O and pressure support up to 7 cm H2O. The SBT shall be terminated and mechanical ventilation reinstituted at the original settings if the patient meets any of the SBT failure criteria. A trial is considered successful and physicians will be asked to approve extubation when the patient can breathe spontaneously for the whole trial. Patients shall be continued to be screened daily until extubation, 21 days after enrolment, performance of tracheostomy, death, or withdrawal of care. All patients shall be followed until hospital discharge or death.

Conditions

Interventions

TypeNameDescription
DEVICERESPINOR DXTBlinded, continuous diaphragmatic excursion measurements by DXT will be conducted during the patients' first SBT. The recording shall be initiated 15 minutes prior to the first SBT and will end 15 minutes post SBT.

Timeline

Start date
2021-05-11
Primary completion
2022-03-30
Completion
2022-04-30
First posted
2021-01-06
Last updated
2023-12-19

Locations

9 sites across 3 countries: France, Italy, Norway

Source: ClinicalTrials.gov record NCT04696406. Inclusion in this directory is not an endorsement.